Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 14/20 | 0.39 |
| ▸ | FNTB | P49356 | 14/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476635 | 0.96 | BMP1 (0.38) | FOLH1FNTAFNTBPGGT1BNAALAD2 | |
| SCHEMBL29842532 | 0.92 | NAALAD2 (0.38) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL30692040 | 0.92 | NAALAD2 (0.38) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL30008175 | 0.92 | BACE1 (0.40) | FNTAFNTBPGGT1BBMP1 | |
| SCHEMBL38651064 | 0.91 | NAALAD2 (0.38) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL31757519 | 0.91 | NAALAD2 (0.38) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL31757514 | 0.91 | BACE1 (0.39) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL31757521 | 0.91 | NAALAD2 (0.38) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL29749072 | 0.91 | FNTA (0.38) | FNTAFNTBPGGT1B | |
| SCHEMBL29381057 | 0.91 | FNTA (0.38) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667215-B | Broad-spectrum antiviral medicine for resisting coronavirus | 堪萨斯州立大学研究基金会 | 2026-05-19 | — | — | CN | disclosed |
| US-12583820-B2 | Broad spectrum antivirals against coronavirus | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250003940-A1 | BIOSENSOR, BIOSENSOR COMPONENTS, AND USE THEREOF | VICTORIA LINK LIMITED (NZ) | 2025-01-02 | — | — | US | disclosed |
| US-20240307419-A1 | CONFORMATIONALLY-CONSTRAINED INHIBITORS OF 3C OR 3C-LIKE PROTEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-19 | — | — | US | disclosed |
| CN-116377019-A | Dual screening method for viral 3C protease inhibitor based on FRET and stress particles | 浙江师范大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-115667215-A | Broad-spectrum antiviral medicine for resisting coronavirus | 堪萨斯州立大学研究基金会 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583820-B2 | Broad spectrum antivirals against coronavirus | SARS1, NSUN2, ZC3HAV1 | FOLH1 3080/4885FNTA 4673/4885FNTB 4514/4885 |
| US-20240307419-A1 | CONFORMATIONALLY-CONSTRAINED INHIBITORS OF 3C OR 3C-LIKE PROTEASES | GTF3C3, GTF3C4, GTF3C2 | FOLH1 2474/4885FNTA 3707/4885FNTB 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.